# Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism

Study · id `cardio:ct-nct02132689` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02132689](<https://clinicaltrials.gov/study/NCT02132689>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02132689

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT02132689. Non-randomized; no masking; primary purpose treatment. Start 2011-03 (actual); primary completion 2015-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT02132689, source copy `cardio:ctgov-nct02132689-2018-03-19`, retrieved 2026-10-31)
- Started: 2011-03 (actual) (ClinicalTrials.gov record NCT02132689, source copy `cardio:ctgov-nct02132689-2018-03-19`, retrieved 2026-10-31)
- Primary completion: 2015-05 (actual) (ClinicalTrials.gov record NCT02132689, source copy `cardio:ctgov-nct02132689-2018-03-19`, retrieved 2026-10-31)
- Completion: 2015-12 (actual) (ClinicalTrials.gov record NCT02132689, source copy `cardio:ctgov-nct02132689-2018-03-19`, retrieved 2026-10-31)
- Countries: Czechia (ClinicalTrials.gov record NCT02132689, source copy `cardio:ctgov-nct02132689-2018-03-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02132689-2018-03-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism
- Acronym: CONTACT-SPE
- Condition: Pulmonary Embolism
- Intervention (Drug): Actilyse (Thrombolytic therapy)
- Intervention (Drug): Heparine (Standard anticoagulation therapy)
- Lead sponsor: University Hospital Ostrava
- Lead sponsor class: OTHER
- Collaborator: Municipal Hospital Ostrava Fifejdy
- Collaborator class: UNKNOWN
- Collaborator: Silesian Hospital Opava
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: University Hospital Ostrava (`cardio:org-university-hospital-ostrava`)

## Provenance

Content hash: 64662212dcf627377900749b96122cd86daf45257000f83a485d3d243afe6599
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
